Company Filing History:
Years Active: 2003-2004
Title: Imre Domán: Innovator in Pharmaceutical Chemistry
Introduction
Imre Domán is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work has garnered attention in the scientific community.
Latest Patents
Domán's latest patents include a process for the preparation of a 3(2H)-pyridazinone-4-substituted amino 5-chloro derivative. This invention relates to novel processes for synthesizing 5-chloro-4-{3-[N-{2-(3,4-dimethoxyphenyl)-ethyl}-N-methylamino]}-propylamino-3(2H)pyridazinone and its pharmaceutically acceptable acid addition salts. An important feature of this invention is the use of 3,4,5-trichloropyridazone as the starting substance for the synthesis.
Another significant patent involves 8-substituted-9H-1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives, which act as AMPA/kainate receptor inhibitors. This disclosure relates to a novel compound of formula I and its pharmaceutically acceptable quaternary ammonium salts. The patent also describes a process for preparing the compound, a pharmaceutical composition containing it, and a method of treatment using the composition. The compounds possess unique competitive AMPA/kainate antagonist properties, making them useful in treating diseases where inhibition of these receptors may have a favorable effect.
Career Highlights
Imre Domán is associated with Egis Gyógyszergyár Rt., a prominent pharmaceutical company in Hungary. His work at Egis has allowed him to focus on innovative drug development and contribute to advancements in medical science.
Collaborations
Domán has collaborated with notable colleagues such as Gyula Simig and József Barkóczy. Their combined expertise has furthered the research and development of new pharmaceutical compounds.
Conclusion
Imre Domán's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to impact the development of therapeutic agents that may improve patient outcomes.